Unlike treatments that just manage symptoms, Esbriet is a disease-modifying therapy specifically designed to slow IPF progression by targeting multiple pathways involved in lung scarring. It’s taken orally as 267mg capsules, with a gradual dose increase over two weeks to help your body adjust. The final maintenance dose is three capsules taken three times daily with food (nine capsules per day total, equaling 2403mg daily). Taking Esbriet with meals is important because it significantly reduces nausea and dizziness, two common side effects.
How Esbriet Slows Lung Scarring: Idiopathic pulmonary fibrosis causes abnormal scarring (fibrosis) in lung tissue without a known cause. As scar tissue builds up, lungs become stiff and can’t expand properly, making breathing increasingly difficult and reducing oxygen transfer to the blood. While the exact mechanism isn’t fully understood, Esbriet appears to work through multiple pathways to reduce both inflammation and fibrotic processes in the lungs. It helps decrease the production of certain proteins and growth factors that promote scarring and inflammation.
Clinical studies showed Esbriet significantly reduced the decline in lung function compared to placebo. In three major trials involving over 1,200 IPF patients, those taking Esbriet experienced slower decline in forced vital capacity (FVC), a key measure of lung function. Patients on Esbriet lost less lung capacity over time compared to those on placebo, the medication helped preserve breathing ability and slow disease progression. Most patients noticed stabilization of their condition rather than dramatic improvement, which is expected since IPF is a progressive disease.
Dosing Schedule: Treatment starts with a careful two-week titration to minimize side effects. During days 1-7, you take one capsule three times daily with meals. Days 8-14, the dose increases to two capsules three times daily. From day 15 onward, you take the full maintenance dose of three capsules three times daily. This gradual increase helps your body adjust and reduces the likelihood of severe nausea or other gastrointestinal symptoms that sometimes cause people to stop treatment. If you miss 14 or more consecutive days of treatment, you’ll need to restart the titration process.
Esbriet must always be taken with food at the same times each day to maintain consistent blood levels and minimize side effects. Never take more than three doses in one day or double up if you miss a dose. For patients managing multiple conditions with medications from digestive health categories, the gastrointestinal side effects of Esbriet may require additional management strategies.
Important Monitoring Requirements: Before starting Esbriet, you’ll need baseline liver function tests (ALT, AST, and bilirubin). These tests are repeated monthly for the first six months, then every three months afterward since the medication can cause liver enzyme elevations in some patients. Most elevations are mild and reversible with dose adjustment or temporary treatment interruption, but careful monitoring catches problems early. You should immediately report symptoms like yellowing skin or eyes, dark urine, unusual fatigue, or pain in the upper right abdomen.
Esbriet causes photosensitivity in about 9% of patients, meaning your skin becomes much more sensitive to sunlight and you can develop severe sunburn even with brief sun exposure. You must use high SPF sunscreen (SPF 50 or higher), wear protective clothing and a hat, and avoid direct sunlight and tanning beds during treatment. Most photosensitivity reactions occur during the first six months. Similar to patients using Ofev, the other approved IPF medication, sun protection is essential throughout treatment.
If you smoke, discuss smoking cessation with your doctor before starting Esbriet. Smoking significantly decreases pirfenidone blood levels, which may reduce how well the medication works. Smokers have about half the drug exposure compared to non-smokers, potentially making treatment less effective. Your healthcare team can provide resources and support for quitting smoking.


